Ryan D Cassaday

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4035196/publications.pdf

Version: 2024-02-01

63	2,367	304743	223800
papers	citations	22 h-index	46 g-index

64	64	64	2990
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Megadose 90Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma. Blood Advances, 2022, 6, 37-45.	5.2	3
2	Physician and patient perceptions on randomization of treatment intensity for unfit adults with acute myeloid leukemia and other high-grade myeloid neoplasm. Leukemia, 2022, , .	7.2	0
3	Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia. Cancer, 2022, 128, 1411-1417.	4.1	8
4	Yttrium-90 Anti-CD45 Immunotherapy Followed by Autologous Hematopoietic Cell Transplantation for Relapsed or Refractory Lymphoma. Transplantation and Cellular Therapy, 2021, 27, 57.e1-57.e8.	1.2	7
5	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. Blood, 2021, 137, 323-335.	1.4	111
6	Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, 176-181.	0.4	8
7	Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosomeâ€“positive relapsed/refractory acute lymphoblastic leukemia. Cancer, 2021, 127, 905-913.	4.1	30
8	Comparison of outpatient care following intensive induction versus post-remission chemotherapy for adults with acute myeloid leukemia and other high-grade myeloid neoplasms. Leukemia and Lymphoma, 2021, 62, 234-238.	1.3	4
9	Inotuzumab Ozogamicin for Relapsed/Refractory Acute Lymphoblastic Leukemia in the INO-VATE Trial: CD22 Pharmacodynamics, Efficacy, and Safety by Baseline CD22. Clinical Cancer Research, 2021, 27, 2742-2754.	7.0	16
10	KTE-X19 anti-CD19 CAR T-cell therapy in adult relapsed/refractory acute lymphoblastic leukemia: ZUMA-3 phase 1 results. Blood, 2021, 138, 11-22.	1.4	90
11	Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. Leukemia and Lymphoma, 2021, 62, 3333-3347.	1.3	2
12	KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet, The, 2021, 398, 491-502.	13.7	315
13	Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. Lancet Haematology,the, 2021, 8, e562-e571.	4.6	28
14	Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?. Current Oncology, 2021, 28, 252-259.	2.2	5
15	Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL. Blood, 2021, 138, 3872-3872.	1.4	7
16	Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm. Leukemia, 2020, 34, 635-639.	7.2	11
17	Impact of Double- or Triple-Hit Pathology on Rates and Durability of Radiation Therapy Response Among Patients With Relapsed or Refractory Large B-Cell Lymphoma. Practical Radiation Oncology, 2020, 10, 44-52.	2.1	10
18	When a randomized controlled trial is unlikely: Propensity score analysis of blinatumomab in adults with relapsed/refractory Philadelphia chromosomeâ€“positive Bâ€cell acute lymphoblastic leukemia. Cancer, 2020, 126, 253-255.	4.1	2

#	Article	IF	Citations
19	Phase 2 study of pembrolizumab for measurable residual disease in adults with acute lymphoblastic leukemia. Blood Advances, 2020, 4, 3239-3245.	5.2	19
20	Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicin. British Journal of Haematology, 2020, 191, e77-e81.	2.5	3
21	Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clinical Cancer Research, 2020, 26, 1247-1257.	7.0	54
22	Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study database. Leukemia and Lymphoma, 2020, 61, 2012-2015.	1.3	10
23	Considerations for Managing Patients With Hematologic Malignancy During the COVID-19 Pandemic: The Seattle Strategy. JCO Oncology Practice, 2020, 16, 571-578.	2.9	20
24	Biokinetics of Radiolabeled Monoclonal Antibody BC8: Differences in Biodistribution and Dosimetry Among Hematologic Malignancies. Journal of Nuclear Medicine, 2020, 61, 1300-1306.	5.0	4
25	Pembrolizumab with Râ€CHOP in previously untreated diffuse large Bâ€cell lymphoma: potential for biomarker driven therapy. British Journal of Haematology, 2020, 189, 1119-1126.	2.5	69
26	Pembrolizumab with R-CHOP in Previously Untreated Diffuse Large B-Cell Lymphoma: Long Term Follow up and Analysis of the Mechanism of Pdl-1 Tumor Expression. Blood, 2020, 136, 13-14.	1.4	3
27	Predictors of Cytopenia after Treatment with Axicabtagene Ciloleucel in Patients with Large Cell Lymphoma. Blood, 2020, 136, 1-2.	1.4	2
28	Hematopoietic Cell Transplantation in the Treatment of Adult Acute Lymphoblastic Leukemia: Updated 2019 Evidence-Based Review from the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, 2113-2123.	2.0	77
29	Phase I Study of a CD45-Targeted Antibodyâ€“Radionuclide Conjugate for High-Risk Lymphoma. Clinical Cancer Research, 2019, 25, 6932-6938.	7.0	15
30	Outcomes of patients with large Bâ€cell lymphomas and progressive disease following CD19â€specific CAR Tâ€cell therapy. American Journal of Hematology, 2019, 94, E209-E213.	4.1	92
31	Outcomes of Allogeneic Stem Cell Transplantation after Inotuzumab Ozogamicin Treatment for Relapsed or Refractory Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2019, 25, 1720-1729.	2.0	53
32	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. Blood, 2019, 133, 1652-1663.	1.4	277
33	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. Blood, 2019, 133, 1876-1887.	1.4	230
34	Safety of allogeneic hematopoietic cell transplant in adults after CD19-targeted CAR T-cell therapy. Blood Advances, 2019, 3, 3062-3069.	5.2	74
35	Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes. Blood Advances, 2019, 3, 4228-4237.	5.2	34
36	Description and prognostic significance of the kinetics of minimal residual disease status in adults with acute lymphoblastic leukemia treated with HyperCVAD. American Journal of Hematology, 2018, 93, 546-552.	4.1	13

#	Article	IF	Citations
37	Prognostic impact of incomplete hematologic count recovery and minimal residual disease on outcome in adult acute lymphoblastic leukemia at the time of second complete response. Leukemia and Lymphoma, 2018, 59, 363-371.	1.3	4
38	Total Body Irradiation Is Safe and Similarly Effective as Chemotherapy-Only Conditioning in Autologous Stem Cell Transplantation for Mantle Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 282-287.	2.0	8
39	Long-Term Follow-Up of 90Y-Ibritumomab Tiuxetan, Fludarabine, and Total Body Irradiationâ€"Based Nonmyeloablative Allogeneic Transplant Conditioning for Persistent High-Risk B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2018, 24, 2211-2215.	2.0	9
40	Outcomes of Patients with Large B-Cell Lymphomas and Progressive Disease Following CD19-Specific CAR T-Cell Therapy. Blood, 2018, 132, 94-94.	1.4	10
41	Efficacy and Toxicity of JCAR014 in Combination with Durvalumab for the Treatment of Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma. Blood, 2018, 132, 1680-1680.	1.4	31
42	Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5 and Leukemia, 2017, 17, 225-230.	0.4	17
43	NCCN Guidelines Insights: Acute Lymphoblastic Leukemia, Version 1.2017. Journal of the National Comprehensive Cancer Network: JNCCN, 2017, 15, 1091-1102.	4.9	67
44	Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, e87-e90.	0.4	3
45	Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematology,the, 2017, 4, e387-e398.	4.6	158
46	Spontaneous Remission of an Untreated, MYC and BCL2 Coexpressing, High-Grade B-Cell Lymphoma: A Case Report and Literature Review. Case Reports in Hematology, 2017, 2017, 1-6.	0.4	8
47	Evaluation of allogeneic transplantation in first or later minimal residual disease â€" negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leukemia and Lymphoma, 2016, 57, 2109-2118.	1.3	28
48	An unusual case of co-existing classic mantle cell lymphoma and transformed lymphoma with Burkitt-like features with leukemic presentation. Journal of Hematopathology, 2016, 9, 91-99.	0.4	1
49	Safety and Activity of Brentuximab Vedotin (BV) Plus Ifosfamide, Carboplatin, and Etoposide (ICE) for Relapsed/Refractory (Rel/Ref) Classical Hodgkin Lymphoma (cHL): Initial Results of a Phase I/II Trial. Blood, 2016, 128, 1834-1834.	1.4	42
50	Real World Utilization and Practice Patterns of Dose-Adjusted EPOCH for Aggressive B-Cell Lymphomas 2005-2015: Impact of Growth Factor Choice and Resultant Achieved Dose Level. Blood, 2016, 128, 3577-3577.	1.4	0
51	Prognostic Parameters in Adults with Acute Lymphoblastic Leukemia at Second Complete Response. Blood, 2016, 128, 1603-1603.	1.4	0
52	Acute Lymphoblastic Leukemia, Version 2.2015. Journal of the National Comprehensive Cancer Network: JNCCN, 2015, 13, 1240-1279.	4.9	116
53	High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma. British Journal of Haematology, 2015, 171, 788-797.	2.5	11
54	A Phase II, Single-Arm, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of P276-00, a Cyclin-Dependent Kinase Inhibitor, in Patients With Relapsed or Refractory Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 392-397.	0.4	52

#	Article	IF	Citations
55	Long-Term Outcomes of Patients with Persistent Indolent BÂCell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. Biology of Blood and Marrow Transplantation, 2015, 21, 281-287.	2.0	19
56	Brentuximab vedotin administered to platinumâ€refractory, transplantâ€naÃ¨ve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status. Hematological Oncology, 2015, 33, 187-191.	1.7	10
57	Analysis of Pre-Transplant Therapy with Brentuximab Vedotin for Relapsed/Refractory Hodgkin Lymphoma on Outcomes of Reduced Intensity Conditioned Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 4406-4406.	1.4	2
58	A Phase II Trial of Radioimmunotherapy-Based Autologous Transplantation with I-131 Tositumomab, Cyclophosphamide and Etoposide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Blood, 2015, 126, 5502-5502.	1.4	0
59	Myeloablative I-131-Tositumomab with Escalating Doses of Fludarabine and Autologous Hematopoietic Transplantation for Adults Age â‰¥ 60ÂYears with B Cell Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 770-775.	2.0	21
60	Allogeneic hematopoietic cell transplantation in mantle cell lymphoma. Best Practice and Research in Clinical Haematology, 2012, 25, 165-174.	1.7	6
61	What Is the Role of Transplantation for Indolent Lymphoma?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2012, , 494-500.	3.8	1
62	Regression of Hodgkin Lymphoma After Discontinuation of a Tumor Necrosis Factor Inhibitor for Crohn's Disease: A Case Report and Review of the Literature. Clinical Lymphoma, Myeloma and Leukemia, 2011, 11, 289-292.	0.4	23
63	Asparaginase in the Treatment of Acute Lymphoblastic Leukemia in Adults: Current Evidence and Place in Therapy. Blood and Lymphatic Cancer: Targets and Therapy, 0, Volume 12, 55-79.	2.7	14